|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute of Mental Health (NIMH) |
|---|---|
| Information provided by: | National Institute of Mental Health (NIMH) |
| ClinicalTrials.gov Identifier: | NCT00080158 |
Purpose
The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.
| Condition | Intervention | Phase |
|---|---|---|
|
Depression Suicide, Attempted |
Drug: fluoxetine Drug: sertraline Drug: citalopram Drug: escitalopram Drug: bupropion Drug: mirtazapine Drug: venlafaxine Drug: lithium Behavioral: Cognitive Behavioral Therapy |
Phase II Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Estimated Enrollment: | 120 |
| Study Start Date: | March 2004 |
| Study Completion Date: | June 2007 |
Suicide is the third leading cause of death in adolescents and is a major public health problem. Depression is the most common diagnosis for adolescent suicide attempts. Little is known about what treatment is best for these adolescents since they are usually excluded from participation in research studies.
Participants in this study will be randomly assigned to receive carefully monitored antidepressant medication with routine support and management, cognitive behavioral therapy (CBT), or a combination of antidepressant medication plus CBT.
Eligibility| Ages Eligible for Study: | 12 Years to 18 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Contacts and Locations| United States, Maryland | |
| Johns Hopkins University | |
| Baltimore, Maryland, United States, 21287 | |
| United States, New York | |
| Columbia University at the New York State Psychiatric Institute | |
| New York, New York, United States, 10032 | |
| New York University Child Study Center | |
| New York, New York, United States, 10016 | |
| United States, North Carolina | |
| Duke University Medical Center | |
| Durham, North Carolina, United States, 27705 | |
| United States, Pennsylvania | |
| University of Pittsburgh - Western Psychiatric Institute and Clinic | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| United States, Texas | |
| University of Texas, Southwestern Medical Center | |
| Dallas, Texas, United States, 75235 | |
| Study Chair: | Laurence Greenhill, MD |
More Information
| Study ID Numbers: | U10 MH66762, U10 MH066775, U10 MH066778, U10 MH066769, U10 MH066750, DDTR B4-ARD |
| Study First Received: | March 24, 2004 |
| Last Updated: | July 17, 2008 |
| ClinicalTrials.gov Identifier: | NCT00080158 |
| Health Authority: | United States: Food and Drug Administration |
|
Dysthymic Disorder Adolescent |
|
Depression Suicide, Attempted Suicide Lithium Carbonate Mirtazapine Depressive Disorder Citalopram Serotonin Histamine Behavioral Symptoms |
Fluoxetine Venlafaxine Bupropion Histamine phosphate Sertraline Dysthymic Disorder Dexetimide Lithium Self-Injurious Behavior |
|
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Histamine Agents Adrenergic alpha-Antagonists Serotonin Uptake Inhibitors Pharmacologic Actions |
Antidepressive Agents, Tricyclic Serotonin Agents Histamine Antagonists Therapeutic Uses Histamine H1 Antagonists Adrenergic Antagonists Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |
